HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Union animal testing reg

This article was originally published in The Rose Sheet

Executive Summary

Commission Chemicals Policy White Paper is inconsistent with Parliament's position on animal testing in the Seventh Amendment to the cosmetics directive, European Cosmetic, Toiletry and Perfumery Association maintains in an Oct. 15 statement. "The principal of animal testing where indispensable is recognized in the White Paper on Chemicals: continuing to discriminate against the cosmetics industry on this point is not coherent," Colipa says, noting the cosmetics industry uses chemical ingredients. "Furthermore, it means concentrating on only .3% of the problem," Colipa adds. Chemicals Policy proposes safety assessments for roughly 100,000 chemical substances, which could necessitate animal testing, a measure that is banned under the proposed seventh amendment. The White Paper, which was adopted at the EU committee level Oct. 16, is scheduled for debate before full Parliament Nov. 14...

You may also be interested in...

EU chemical white paper moves forward

European Parliament approves Commission White Paper on Strategy for a Future Chemicals Policy Nov. 15, paving the way for future legislation proposal to be developed in 2002, Parliament announces. Draft text should be finalized in late December, according to Rapporteur Inger Schörling's office. Paper, which calls for "better public information on all chemicals," would require comprehensive minimum data requirements for as many as 100,000 chemicals, including some used in cosmetics. Proposed safety assessments could necessitate animal testing, an allowance the European Cosmetic, Toiletry and Perfumery Association criticized as inconsistent and discriminatory in an Oct. 15 statement (1"The Rose Sheet" Nov. 12, In Brief)...

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts